GlassScriptPhysician profile
Rachel L Paskey
NPI 1659659340
$6,031.84
in general payments reported to CMS, 2019-2025
33 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,399 · 2022: $1,800 · 2023: $2,212 · 2024: $334 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.29 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $970.20 | 2021-2023 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $565.73 | 2021-2023 | Stelara, Simponi, Remicade |
| Ferring Pharmaceuticals INC. | $312.70 | 2021-2023 | Rebyota, Clenpiq |
| Celgene Corporation | $275.43 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $221.08 | 2021-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $201.21 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $195.31 | 2021-2023 | Entyvio |
| Ardelyx, INC. | $175.49 | 2022 | |
| Genzyme Corporation | $163.59 | 2022-2023 | |
| Amgen INC. | $155.95 | 2021-2024 | Krystexxa |
| Nestle Healthcare Nutrition INC. | $153.27 | 2021-2023 | |
| Braintree Laboratories, INC. | $147.64 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $139.08 | 2021-2023 | Linzess |
| Ani Pharmaceuticals, INC. | $124.96 | 2023 | Purified Cortrophin Gel |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.96 | 2023 | Farxiga |
| Pfizer INC. | $123.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $120.33 | 2022 | |
| Fresenius USA Marketing, INC. | $120.14 | 2024-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $111.38 | 2024-2025 | |
| Qol Medical, LLC | $85.38 | 2021-2023 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.91 | 2023-2024 | Cyltezo, Jardiance |
| Gilead Sciences, INC. | $56.87 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $50.87 | 2023 | |
| Vifor Pharma, INC. | $46.20 | 2024 | Veltassa |
| Boston Scientific Corporation | $32.89 | 2025 | General - Pain Management |
| Organon LLC | $30.72 | 2023 | Renflexis |
| Intercept Pharmaceuticals, INC. | $23.87 | 2023 | Ocaliva |
| Lilly USA, LLC | $22.48 | 2024 | Jardiance |
| Kyowa Kirin, INC. | $22.36 | 2024 | Crysvita |
| Akebia Therapeutics INC | $20.14 | 2024 | Auryxia |
| Cumberland Pharmaceuticals, INC. | $17.67 | 2023 | Kristalose |
| Alfasigma USA, INC. | $15.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Paskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.